Bluejay Diagnostics (NASDAQ:BJDX) Rating Lowered to Sell at Wall Street Zen

Bluejay Diagnostics (NASDAQ:BJDX) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Monday, Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Bluejay Diagnostics currently has an average rating of “Sell”.

Bluejay Diagnostics Stock Performance

BJDX stock opened at $0.85 on Monday. The business has a 50-day simple moving average of $1.04 and a two-hundred day simple moving average of $1.90. The company has a market capitalization of $3.79 million, a P/E ratio of -0.12 and a beta of 0.91. Bluejay Diagnostics has a 52-week low of $0.82 and a 52-week high of $16.68.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($1.12) EPS for the quarter, topping the consensus estimate of ($3,520.00) by $3,518.88.

Insider Activity at Bluejay Diagnostics

In other news, major shareholder Financial Lp Hrt sold 34,938 shares of Bluejay Diagnostics stock in a transaction on Friday, July 10th. The stock was sold at an average price of $1.40, for a total transaction of $48,913.20. Following the sale, the insider directly owned 92,055 shares in the company, valued at $128,877. The trade was a 27.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.10% of the stock is owned by insiders.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.